Anixa Biosciences Inc 10-Q

Financial Statements (unaudited)

Item 1. Financial Statements. ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and per share data) July 31, 2026 October 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 1,398 $ 1,244 Short-term investments 12,466 13,930 Prepaid expenses and other current assets 1,047 713 Total current assets 14,911 15,887 Operating lease right-of-use asset 163 193 Total assets $ 15,074 $ 16,080 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 282 $ 165 Accrued expenses 1,417 1,761 Operating lease liability, current 46 41 Total current liabilities 1,745 1,967 Operating lease liability, non-current 128 163 Total liabilities 1,873 2,130 Commitments and contingencies (Note 10) - - Equity: Shareholders’ equity: Preferred stock, par value $ 100 per share; 19,860 shares authorized; no shares issued or outstanding - - Series A convertible preferred stock, par value $ 100 per share; 140 shares authorized; no shares issued or outstanding - - Preferred stock, value - - Common stock, par value $ .01 per share; 100,000,000 shares authorized; 34,584,538 and 33,013,829 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively 346 330 Additional paid-in capital 273,489 266,508 Accumulated deficit ( 259,364 ) ( 251,677 ) Total shareholders’ equity 14,471 15,161 Noncontrolling interest (Note 2) ( 1,270 ) ( 1,211 ) Total equity 13,201 13,950 Total liabilities and equity $ 15,074 $ 16,080 The accompanying notes are an integral part of these condensed consolidated financial statements. Field: Page; Sequence: 3; Options: NewSection Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence Field: /Page ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except per share data) 2026 2025 2026 2025 For the three months ended For the nine months ended July 31, July 31, 2026 2025 2026 2025 Revenue $ - $ - $ - $ - Operating expenses: Research and development expenses (including non-cash stock-based compensation expenses of $ 286 , $ 358 , $ 909 and $ 1,172 , respectively) 1,326 1,055 3,686 3,929 General and administrative expenses (including non-cash stock-based compensation expenses of $ 380 , $ 497 , $ 1,218 and $ 1,727 , respectively) 1,411 1,381 4,414 4,896 Total operating expenses 2,737 2,436 8,100 8,825 Loss